A detailed history of China Universal Asset Management Co., Ltd. transactions in Alector, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 18,718 shares of ALEC stock, worth $34,815. This represents 0.01% of its overall portfolio holdings.

Number of Shares
18,718
Previous 11,323 65.31%
Holding current value
$34,815
Previous $51,000 70.59%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$4.34 - $6.58 $32,094 - $48,659
7,395 Added 65.31%
18,718 $87,000
Q2 2024

Jul 19, 2024

SELL
$4.19 - $6.23 $29,665 - $44,108
-7,080 Reduced 38.47%
11,323 $51,000
Q1 2024

Apr 29, 2024

BUY
$5.69 - $8.08 $49,332 - $70,053
8,670 Added 89.08%
18,403 $111,000
Q4 2023

May 21, 2024

SELL
$3.77 - $8.39 $32,685 - $72,741
-8,670 Reduced 47.11%
9,733 $77,000
Q4 2023

Jan 23, 2024

BUY
$3.77 - $8.39 $28,591 - $63,629
7,584 Added 352.91%
9,733 $78,000
Q3 2023

May 21, 2024

BUY
$5.2 - $8.77 $5,491 - $9,261
1,056 Added 96.61%
2,149 $13,000
Q3 2023

Oct 30, 2023

BUY
$5.2 - $8.77 $5,491 - $9,261
1,056 Added 96.61%
2,149 $14,000
Q2 2023

May 21, 2024

SELL
$5.86 - $7.93 $187 - $253
-32 Reduced 2.84%
1,093 $6,000
Q2 2023

Jul 27, 2023

SELL
$5.86 - $7.93 $187 - $253
-32 Reduced 2.84%
1,093 $7,000
Q1 2023

May 21, 2024

BUY
$5.85 - $9.84 $1,667 - $2,804
285 Added 33.93%
1,125 $6,000
Q1 2023

Apr 27, 2023

BUY
$5.85 - $9.84 $1,667 - $2,804
285 Added 33.93%
1,125 $7,000
Q4 2022

May 21, 2024

SELL
$6.88 - $9.55 $120,833 - $167,726
-17,563 Reduced 95.44%
840 $7,000
Q4 2022

Jan 31, 2023

BUY
$6.88 - $9.55 $460 - $639
67 Added 8.67%
840 $8,000
Q3 2022

Oct 21, 2022

BUY
$8.19 - $13.2 $6,330 - $10,203
773 New
773 $7,000

Others Institutions Holding ALEC

About Alector, Inc.


  • Ticker ALEC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,563,904
  • Market Cap $154M
  • Description
  • Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...
More about ALEC
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.